A new expression plasmid in Bifidobacterium longum as a delivery system of endostatin for cancer gene therapy

Cancer Gene Therapy

Volumn 14, Issue 2, 2007, Pages 151-157

  Xu, Y F ^a   Zhu, L P ^a   Hu, B ^a   Fu, G F ^a   Zhang, H Y ^a   Wang, J J ^a,b   Xu, G X ^a,c  

^a NANJING UNIVERSITY   (China)

^b NANJING NORMAL UNIVERSITY   (China)

^c Jiangsu Research Center for Gene Pharmaceutical Engineering and Technology   (China)

Author keywords

Bifidobacterium longum; Endostatin; Plasmid stability; Tumor

Indexed keywords

ENDOSTATIN;

AMINO TERMINAL SEQUENCE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BACTERIAL STRAIN; BIFIDOBACTERIUM LONGUM; CANCER GENE THERAPY; CANCER INHIBITION; CONTROLLED STUDY; ELECTROPORATION; MALE; MOLECULAR CLONING; MOUSE; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; PLASMID; PRIORITY JOURNAL; PROTEIN EXPRESSION; SOLID TUMOR; STATISTICAL SIGNIFICANCE;

ANIMALS; BASE SEQUENCE; BIFIDOBACTERIUM; DNA PRIMERS; DRUG RESISTANCE; ELECTROPORATION; ENDOSTATINS; MICE; NEOPLASMS, EXPERIMENTAL; PLASMIDS;

BIFIDOBACTERIUM LONGUM;

EID: 33846203929     PISSN: 09291903     EISSN: 14765500     Source Type: Journal    
DOI: 10.1038/sj.cgt.7701003     Document Type: Article

References (25)

1. Kimura NT, Taniguchi S, Aoki K, Baba T. Selective localization and growth of Bifidobacterium bifidum in mouse tumors following intravenous administration. Cancer Res 1980; 40: 2061-2068.
2. Missich R, Sgorbati B, LeBlanc DJ. Transformation of Bifidobacterium longum with pRM2, a constructed Escherichia coli-B.longum shuttle vector. Plasmid 1994; 32: 208-211.
3. Rossi M, Brigidi P, Matteuzzi D. An efficient transformation system for Bifidobacterium spp. Lett Appl Microbiol 1997; 24: 33-36.
4. Rossi M, Brigidi P, Matteuzzi D. Improved cloning vectors for Bifidobacterium spp. Lett Appl Microbiol 1998; 26: 101-104.
5. Rossi M, Brigidi P, Gonzalez Vara y Rodriguez A, Matteuzzi D. Characterization of the plasmid pMB1 from Bifidobacterium longum and its use for shuttle vector construction. Res Microbiol 1996; 147: 133-143.
6. Park MS, Shin DW, Lee KH, Ji GE. Sequence analysis of plasmid pKJ50 from Bifidobacterium longum. Microbiology 1999; 145: 585-592.
7. Yazawa K, Fujimori M, Nakamura T, Sasaki T, Amano J, Kano Y et al. Bifidobacterium longum as a delivery system for gene therapy of chemically induced rat mammary tumors. Breast Cancer Res Treat 2001; 66: 165-170.
8. Nakamura T, Sasaki T, Fujimori M, Yazawa K, Kano Y, Amano J et al. Cloned cytosine deaminase gene expression of Bifidobacterium longum and application to enzyme/pro-drug therapy of hypoxic solid tumors. Biosci Biotechnol Biochem 2002; 66: 2362-2366.
9. Li X, Fu GF, Fan YR, Liu WH, Liu XJ, Wang JJ et al. Bifidobacterium adolescentis as a delivery system of endostatin for cancer gene therapy: selective inhibitor of angiogenesis and hypoxic tumor growth. Cancer Gene Ther 2003; 10: 105-111.
10. Fu GF, Li X, Hou YY, Fan YR, Liu WH, Xu GX. Bifidobacterium longum as an oral delivery system of endostatin for gene therapy on solid liver cancer. Cancer Gene Ther 2005; 12: 133-140.
11. Yi C, Huang Y, Guo ZY, Wang SR. Antitumor effect of cytosine deaminase/5-fluorocytosine suicide gene therapy system mediated by Bifidobacterium infantis on melanoma. Acta Pharmacol Sin 2005; 26: 629-634.
12. Wei YQ, Wang QR, Zhao X, Yang L, Tian L, Lu Y et al. Immunotherapy of tumors with xenogeneic endothelial cells as a vaccine. Nat Med 2000; 6: 1160-1166.
13. Wei YQ, Huang MJ, Yang L, Zhao X, Tian L, Lu Y et al. Immunogene therapy of tumors with vaccine based on Xenopus homologous vascular endothelial growth factor as a model antigen. Proc Natl Acad Sci 2001; 98: 11545-11550.
14. Wang J, Chen C, Li B, Yu H, Zhao Y, Sun J et al. Antioxidative function and biodistribution of [Gd@C82(OH)22]n nanoparticles in tumor-bearing mice. Biochem Pharmacol 2006; 71: 872-881.
15. Boehm T, Folkman J, Browder T, O'Reilly MS. Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance. Nature 1997; 390: 404-407.
16. Smeianov VV, Efimov BA, Korschunov VM, Steele JL. Characterization of plasmid p4M from Bifidobacterium pseudocatenulatum. GenBank 2002; Accession No AF359574.
17. Kaufmann P, Pfefferkorn A, Teuber M, Meile L. Complete nucleotide sequence of the 2.1 kb plasmid pAP1 isolated from Bifidobacterium asteroides. GenBank 1997; Accession No Y11549.
18. O'Riordan K, Fitzgerald GF. Molecular characterisation of a 5.75-kb cryptic plasmid from Bifidobacterium breve NCFB 2258 and determination of mode of replication. FEMS Microbiol Lett 1999; 174: 285-294.
19. Park MS, Lee KH, Ji GE. Isolation and characterization of two plasmids from Bifidobacterium longum. Lett Appl Microbiol 1997; 25: 5-7.
20. Tanaka K, Samura K, Kano Y. Structural and functional analysis of pTB6 from Bifidobacterium longum. Biosci Biotechnol Biochem 2005; 69: 422-455.
21. Gonzalez Vara A, Rossi M, Altomare L, Eikmanns B, Matteuzzi D. Stability of recombinant plasmids on the continuous culture of Bifidobacterium animalis ATCC 27536. Biotechnol Bioeng 2003; 84: 145-150.
22. Zhu L, Li W, Dong X. Species identification of genus Bifidobacterium based on partial HSP60 gene sequences and proposal of Bifidobacterium thermacidophilum subsp. porcinum subsp. nov. Int J Syst Evol Microbiol 2003; 53: 1619-1623.
23. O'Reilly MS, Boehm T, Shing Y, Fukai N, Vasios G, Lane WS et al. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell 1997; 88: 277-285.
24. Tjin Tham Sjin RM, Satchi-Fainaro R, Birsner AE, Ramanujam VM, Folkman J, Javaherian K. A 27-amino-acid synthetic peptide corresponding to the NH2-terminal zinc-binding domain of endostatin is responsible for its antitumor activity. Cancer Res 2005; 65: 3656-3663.
25. Rothbard JB, Garlington S, Lin Q, Kirschberg T, Kreider E, McGrane PL et al. Conjugation of arginine oligomers to cyclosporin A facilitates topical delivery and inhibition of inflammation. Nat Med 2000; 6: 1253-1257.